Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Uday Kiran Veldandi"'
Autor:
Gonzalo, Sapisochin, Wei Chen, Lee, Dong Jin, Joo, Jae-Won, Joh, Koichiro, Hata, Arvinder Singh, Soin, Uday Kiran, Veldandi, Shuhei, Kaneko, Matthias, Meier, Denise, Leclair, Gangadhar, Sunkara, Long Bin, Jeng
Publikováno v:
Annals of Transplantation. 27
BACKGROUND The study objective was to evaluate the effect of everolimus (EVR) in combination with reduced tacrolimus (rTAC) compared with a standard TAC (sTAC) regimen on hepatocellular carcinoma (HCC) recurrence in de novo living-donor liver transpl
Autor:
Rashid Khan Pathan, Uday Kiran Veldandi, Krishna Duvvuri, Rajesh Karan, Fritjof Reinhardt, Sunil Modali, Nikolaos Scarmeas
Publikováno v:
Current Alzheimer research. 18(4)
Background: Transdermal patches are convenient to use, especially in Rotkreuz ZG Rotkreuz ZG patients with Alzheimer’s disease (AD)-associated dementia. However, various identified risks of errors in administering the patches cannot be disregarded.
Autor:
Caroline Derne, GangaRaju Golla, Eric Legangneux, Shibadas Biswal, Uday Kiran Veldandi, Naguib Muhsen
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 52:996-1004
OBJECTIVE To evaluate the effects of siponimod (BAF312) on the pharmacokinetics (PK) and pharmacodynamics (PD) of a monophasic oral contraceptive (OC). MATERIALS AND METHODS This was a phase 1, single-center, open-label, multipledose, single-sequence
Autor:
Aslanis, Kasra Shakeri-Nejad, Zaehringer A, Anne Gardin, Angela Dodman, Uday Kiran Veldandi, Su Z, Eric Legangneux
Publikováno v:
International journal of clinical pharmacology and therapeutics. 55(1)
To assess the pharmacokinetics (PK), safety, and tolerability of siponimod and major metabolites in subjects with mild, moderate, and severe hepatic impairment (HI) compared with demographically-matched healthy subjects (HS).This open-label, parallel
Autor:
Uday Kiran Veldandi, Javier de las Heras, Srividya Ramreddy, Srinivas Martha, Narayana Pantam
Publikováno v:
Asian Journal of Medical Sciences, Vol 2, Iss 1, Pp 56-62 (2011)
Type-2 diabetes is a chronic metabolic progressive disease, affects 200 million people worldwide will leads to increased death by more than 50% in the next 10 years. The ingested nutrients stimulate the release of gut peptides called incretins, which
Autor:
Eric Legangneux, Robert Perry, Florine Polus, Parsar Pal, Shibadas Biswal, Uday Kiran Veldandi, Thomas C. Marbury
Publikováno v:
International journal of clinical pharmacology and therapeutics. 53(10)
Objective To evaluate the cardiac and pulmonary effects of siponimod (BAF312) and propranolol co-administration in healthy subjects. Methods Healthy subjects (n=76) were randomized in a doubleblind manner to receive propranolol at siponimod steady st
Autor:
Axel Juan, Nicole Pezous, Robert Perry, Uday Kiran Veldandi, Eric Legangneux, Louise Mooney, Bruno Brendani, Kasra Shakeri-Nejad, Vassilios Aslanis, Mark Allison
Publikováno v:
Clinical Therapeutics. 37:2489-2505.e2
Purpose The International Conference on Harmonisation E14 guideline mandates an intensive cardiac safety evaluation in a clinical thorough QT study, typically in healthy subjects, for all new non-antiarrhythmic drugs with systemic bioavailability. Th
Publikováno v:
Asian Pacific journal of cancer prevention : APJCP. 11(1)
Tumor markers are biochemical substances elaborated by tumor cells either due to the cause or effect of malignant processes. Here we investigated serum levels of cancer antigen (CA15.3) and carcino embryonic antigen (CEA) in 153 pre and post operated
Autor:
Sapisochin, Gonzalo, Wei Chen Lee, Dong Jin Joo, Jae-Won Joh, Koichiro Hata, Soin, Arvinder Singh, Veldandi, Uday Kiran, Shuhei Kaneko, Meier, Matthias, Leclair, Denise, Sunkara, Gangadhar, Long Bin Jeng
Publikováno v:
Annals of Transplantation; 11/22/2022, Vol. 27, p1-13, 13p
Publikováno v:
Reviews in Analytical Chemistry; 2010, Vol. 29 Issue 1, p59-67, 9p